Melanoma Vaccines: Comparing Novel Adjuvant Treatments in High-Risk Patients
<b>Background:</b> The emergence of checkpoint inhibitors (CPIs) has significantly improved survival outcomes in later-stage melanoma. However, the efficacy of these treatments remains limited, with around 50% of later-stage melanoma patients experiencing recurrence. As variable response...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Artikel |
| Sprache: | Englisch |
| Veröffentlicht: |
MDPI AG
2025-06-01
|
| Schriftenreihe: | Vaccines |
| Schlagworte: | |
| Online-Zugang: | https://www.mdpi.com/2076-393X/13/6/656 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|